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Effect of FK 506 on Human Pancreatic Islets Following Renal 
Subcapsular Transplantation in Diabetic Nude Mice 
C. Ricordi, Y. Zeng, R. Alejandro, A. Tzakis, P. Carroll, H.L.R. Rilo, R. Venkataramanan, J.J. Fung, 
D. Bereiter, and T.E. Starzl 
POSTIRANSPLANT hyperglycemia is a well-recog-
nized side effect of most standard immunosuppres-
sive drugs including prednisone I and cyclosporine 
(CyA),2.-4 which are known to be diabetogenic in humans. 
Similar effects have been ascribed to FK S06 in both 
experimental5.6 and clinical studies.7 The aim of this study 
was to test the in vivo effect of FK S06 on human 
pancreatic islets. 
MATERIALS AND METHODS 
Human islets were preparedK~·9 One week after human islet 
transplantation the ammals were divided into four groups. In 
group I (n = 10). the animals receIved one injection of 0.5 mL of 
cremaphor-ethanol-saline (without FK 506) intrapelitoneaUy HP) 
daily for I week. In group 2 (n = 5). the animals were treated by 
daily IP injection of 0.3 mglkg FK 506. while in groups 3 (n = 5) 
and 4 In = 5) the daily injections were I and 3 mglkg FK 506. 
respectively. 
Fifteen days after islet transplantation. the animals underwent 
IP glucose tolerance test ((PGrn. 10 
RESULTS AND DISCUSSION 
IP administration of FK S06 for I week at a dose of 0.3 
mglkgld did not produce any significant alteration of glu-
cose disappearance after IP administration of glucose. 
Higher doses of FK S06 produced a significant delay in 
plasma glucose disappearance. In groups 3 and 4.2 of \0 
animals demonstrated hyperglycemia before IPGTI (fast-
ing plasma glucose > 200 mgldU. In these animals. the 
presence offasting hyperglycemIa despite normal levels of 
human C-peptide indicated that peripheral insulin resis-
tance could be responsible for the hyperglycemic effect of 
FK 506. Nevertheless, at high dose treatment insulin 
secretion appears to be impaired as well. Furthermore. 5 of 
10 animals remained hyperglycemic 1 hour after IP glucose 
injection. Human C-peptide levels following IPGTI indi-
cated that abnormal glucose disappearance in group 4 was 
associated with an initial impairment of insulin secretion 
from the engrafted islets. In fact. 15 minutes after glucose 
injection a decrease in human C-peptide levels was ob-
served in group 4. in contrast to the control groups in 
which a twofold increase in C-peptide was observed. The 
difference in C-peptide levels between the two groups was 
statistically significant only at the 15 minute level (P < 
.028). 
Histologic studies on the renal subcapsular islets indi-
cated that human islets were present in the renal subcap-
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sular space of all transplanted animals. Nevertheless. in 
the two animals (one in group 3 and one in group 4) that 
were hyperglycemic. the beta cells appeared degranulated. 
In the remaining animals the human islets appeared well 
preserved with no significant difference between FK S06-
treated and control animals. In group I (control) a nephrec-
tomy of the kidneys bearing the grafts produced a rapid 
return to the diabetic state. indicating that the human islets 
transplanted were responsible for the maintenance of 
normoglycemia. 
This study indicates that FK 506 did not produce signif-
icant alteration of glucose homeostasis in animals treated 
with a dose of 0.3 mglkgld for 7 days. Nevertheless. the 
effect of the drug on insulin secretion and glucose disap-
pearance after IP glucose have been observed at higher 
dosages. Although these levels are significantly higher than 
the therapeutic levels in current use in patients, the poten-
tial accumulation during chronic treatment with the agent 
in the pancreas. like CyA. may induce islet secretory 
defects even at therapeutic levels. 
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